- Home
- CSQ vs VKTX Comparison
CSQ vs VKTX Comparison
Compare CSQ & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSQ
- VKTX
- Stock Information
- Founded
- CSQ 2003
- VKTX 2012
- Country
- CSQ United States
- VKTX United States
- Employees
- CSQ N/A
- VKTX N/A
- Industry
- CSQ Finance Companies
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- CSQ Finance
- VKTX Health Care
- Exchange
- CSQ Nasdaq
- VKTX Nasdaq
- Market Cap
- CSQ 3.0B
- VKTX 3.5B
- IPO Year
- CSQ N/A
- VKTX 2015
- Fundamental
- Price
- CSQ $19.15
- VKTX $24.81
- Analyst Decision
- CSQ
- VKTX Strong Buy
- Analyst Count
- CSQ 0
- VKTX 12
- Target Price
- CSQ N/A
- VKTX $87.50
- AVG Volume (30 Days)
- CSQ 220.3K
- VKTX 9.6M
- Earning Date
- CSQ 01-01-0001
- VKTX 10-22-2025
- Dividend Yield
- CSQ 7.53%
- VKTX N/A
- EPS Growth
- CSQ N/A
- VKTX N/A
- EPS
- CSQ N/A
- VKTX N/A
- Revenue
- CSQ N/A
- VKTX N/A
- Revenue This Year
- CSQ N/A
- VKTX N/A
- Revenue Next Year
- CSQ N/A
- VKTX N/A
- P/E Ratio
- CSQ N/A
- VKTX N/A
- Revenue Growth
- CSQ N/A
- VKTX N/A
- 52 Week Low
- CSQ $12.50
- VKTX $18.92
- 52 Week High
- CSQ $16.45
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- CSQ 70.80
- VKTX 36.60
- Support Level
- CSQ $18.30
- VKTX $24.82
- Resistance Level
- CSQ $18.80
- VKTX $26.50
- Average True Range (ATR)
- CSQ 0.13
- VKTX 1.29
- MACD
- CSQ 0.05
- VKTX -0.15
- Stochastic Oscillator
- CSQ 100.00
- VKTX 1.15
About CSQ Calamos Strategic Total Return
Calamos Strategic Total Return Fund is a diversified, closed-end management investment company. The fund's objective is to provide total return through a combination of capital appreciation and current income. Its investment portfolio comprises equities, convertible securities, and high-yield corporate bonds.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.